Jill Ashton

Director Of Business Development at MiBA

Jill Ashton is an accomplished professional with extensive experience in oncology and business development. Currently serving as the Director of Business Development at MiBA since April 2024, Jill partners with Pharma & Biotech, Payers, and Practices to enhance oncology outcomes through comprehensive data solutions. Previously, Jill held the position of Director of Strategic Accounts at GSK from October 2019 to April 2024, focusing on strategy development and innovative partnerships in oncology. Early career roles include Oncology Account Manager positions at Acrotech Biopharma and Spectrum Pharmaceuticals, where Jill achieved top national rankings and led successful product launches. Jill also excelled as an Immunotherapy Sales Specialist at Dendreon and as an Oncology Clinical Specialist at Amgen. Jill began the career as an Oncology Nurse, progressing to Nursing Manager at Carle Foundation Hospital. Jill holds a BSN in Nursing from Murray State University.

Location

Bluffton, United States

Links

Previous companies


Org chart

No direct reports

Teams

This person is not in any teams


Offices


MiBA

MiBA (๐— ๐—ฒ๐—ฎ๐—ป๐—ถ๐—ป๐—ด๐—ณ๐˜‚๐—น ๐—œ๐—ป๐˜€๐—ถ๐—ด๐—ต๐˜๐˜€ | ๐—•๐—ถ๐—ผ๐—ง๐—ฒ๐—ฐ๐—ต ๐—”๐—ป๐—ฎ๐—น๐˜†๐˜๐—ถ๐—ฐ๐˜€) is a healthcare AI technology company on a mission to close the feedback loop between physicians, patients, and industry partners. The technology and data insights that MiBA generates will support pharmaceutical companies, research organizations, payers, biotech, health systems and providers to advance the quality of patient care. Learn more at mibanalytics.com. MiBA's sophisticated platform empowers decision-makers throughout healthcare โ€” physicians, health systems, biopharmaceutical companies and payors โ€” with the data and tools necessary to accelerate research, optimize risk evaluation and reduce costs, enabling more accurate diagnoses and personalized treatment plans. These capabilities are integral components of MiBA's comprehensive suite of services, reflecting its commitment to advancing healthcare insights on a broader scale. As a fast-growing nationwide data platform focused on expansion, MiBA is poised to make significant contributions to oncology care, research and treatment development. The company invites partners, healthcare professionals and the broader community to join in its journey towards harnessing the full potential of data-driven insights in the battle against cancer. For practices looking to unlock and leverage their data assets to enhance clinical efficiency and productivity or for more information about MiBA and its services, visit www.mibanalytics.com .


Industries

Employees

51-200

Links